Author

J.-J. Fournie

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2

Frequent Co-Authors

A. Hedley· 2 shared A. Kilbey· 2 shared K. Blyth· 2 shared M. Tosolini· 2 shared R. Wiesheu· 2 shared S. B. Coffelt· 2 shared S. C. Edwards· 2 shared A. Bousard· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Hedley

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

IL-27 maintains cytotoxic Ly6C+ gamma delta T cells that arise from immature precursors

R. Wiesheu, S. C. Edwards, A. Hedley, M. Tosolini, M. G. F. Fares da Silva, N. Sumaria, Y. Optaczy, D. G. Hill, A. J. Hayes, J. Hay, A. Kilbey, A. M. Michie, G. Graham, A. Manoharan, C. Halsey, , S. B. Coffelt

The paper identifies immature and mature subsets of IFNγ-producing γδ T cells, showing IL-27 supports cytotoxic function in mature cells but not immature ones.

bioRxiv · Oct 26, 2023Immunology

Ly6C defines a subset of memory-like CD27+ γδ T cells with inducible cancer-killing function

R. Wiesheu, S. C. Edwards, A. Hedley, K. Kirschner, M. Tosolini, J.-J. Fournie, A. Kilbey, S.-J. Remak, C. Miller, K. Blyth, S. B. Coffelt

The paper identifies two subsets of CD27+ γδ T cells in mice, distinguished by Ly6C expression, with one subset showing memory-like properties and cancer-killing potential.

bioRxiv · Sep 8, 2020 · PreprintImmunology

Mitochondrial determinants of response and resistance to venetoclax plus cytarabine duplet therapy in acute myeloid leukemia

C. Bosc, N. Gadaud, A. Bousard, M. Sabatier, G. Cognet, E. Saland, T. Farge, E. Boet, M. Gotanegre, N. Aroua, P.-L. Mouchel, C. Larrue, L. Jarrou, F. Rambow, F. Cabon, , J.-E. Sarry

This study identifies mitochondrial determinants of response and resistance to venetoclax plus cytarabine therapy in AML, showing that OxPHOS is a predictive marker and that targeting ETCI improves outcomes.

bioRxiv · Aug 17, 2020 · PreprintCancer Biology